PE20070165A1 - Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazona - Google Patents
Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazonaInfo
- Publication number
- PE20070165A1 PE20070165A1 PE2006000642A PE2006000642A PE20070165A1 PE 20070165 A1 PE20070165 A1 PE 20070165A1 PE 2006000642 A PE2006000642 A PE 2006000642A PE 2006000642 A PE2006000642 A PE 2006000642A PE 20070165 A1 PE20070165 A1 PE 20070165A1
- Authority
- PE
- Peru
- Prior art keywords
- dry weight
- glitazone
- peptidase
- inhibitor
- base
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE TABLETAS FORMADAS MEDIANTE COMPRESION DIRECTA QUE COMPRENDE: A) DE 5 A 65% DE UNA BASE DE PESO SECO DE 2 PRINCIPIOS ACTIVOS: i) UN INHIBIDOR DE DIPEPTIDIL-PEPTIDASA IV TALES COMO L-TREO-ISOLEUCIL-TIAZOLIDINA, 3-(AMINO-METIL)-2-ISOBUTIL-1-OXO-4-FENIL-1,2-DIHIDRO-6-ISOQUINOLIN-CARBOXAMIDA, (S)-1-[(3-HIDROXI-1-ADAMANTIL)-AMINO]ACETIL-2-CIANO-PIRROLIDINA, ENTRE OTROS Y ii) UNA GLITAZONA TALES COMO PIOGLITAZONA O ROSIGLITAZONA; B) DE 30 A 95% DE UNA BASE DE PESO SECO DE UN DILUYENTE A BASE DE CELULOSA MICROCRISTALINA; C) DE 0 A 20% DE UNA BASE DE PESO SECO DE UN DESINTEGRANTE A BASE DE LACTOSA; D) DE 0,1 A 10% DE UNA BASE DE PESO SECO DE UN LUBRICANTE A BASE DE GLICOLATO DE ALMIDON DE SODIO. TAMBIEN SE REFIERE A UN POCESO DE PREPARACION DE DICHA COMPOSICION, EN DONDE LA DISTRIBUCION DE TAMANOS DE PARTICULAS EN LA TABLETA ES MENOR A 250 MICRAS
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68973905P | 2005-06-10 | 2005-06-10 | |
| US69052705P | 2005-06-14 | 2005-06-14 | |
| US69081405P | 2005-06-15 | 2005-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070165A1 true PE20070165A1 (es) | 2007-03-09 |
Family
ID=37198127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000642A PE20070165A1 (es) | 2005-06-10 | 2006-06-08 | Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazona |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080193529A1 (es) |
| EP (1) | EP1893236A2 (es) |
| JP (1) | JP2008543767A (es) |
| KR (1) | KR20080018257A (es) |
| AR (1) | AR054382A1 (es) |
| AU (2) | AU2006258013A1 (es) |
| BR (1) | BRPI0613567A2 (es) |
| CA (1) | CA2610412A1 (es) |
| GT (1) | GT200600218A (es) |
| MX (1) | MX2007015612A (es) |
| PE (1) | PE20070165A1 (es) |
| SA (1) | SA06270158B1 (es) |
| TW (1) | TW200716175A (es) |
| WO (1) | WO2006135693A2 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
| UA95828C2 (ru) | 2007-02-01 | 2011-09-12 | Такеда Фармасьютикал Компани Лимитед | Твердая рецептура, которая содержит алоглиптин и пиоглитазон |
| PE20090597A1 (es) * | 2007-08-16 | 2009-06-06 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| PE20091730A1 (es) * | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| AU2014262269B2 (en) * | 2008-04-03 | 2017-02-02 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| UY32427A (es) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| WO2011012322A2 (en) * | 2009-07-31 | 2011-02-03 | Krka, D.D., Novo Mesto | Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms |
| BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| CN102883711A (zh) * | 2010-05-05 | 2013-01-16 | 贝林格尔.英格海姆国际有限公司 | 包含吡格列酮和利格列汀的药物组合物 |
| EP3366304B1 (en) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| CN102657626B (zh) * | 2012-05-23 | 2013-07-17 | 重庆康刻尔制药有限公司 | 一种盐酸吡格列酮药物组合片剂 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
| WO2015012365A1 (ja) * | 2013-07-25 | 2015-01-29 | 株式会社 三和化学研究所 | 医薬製剤 |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| JP7379189B2 (ja) * | 2020-01-31 | 2023-11-14 | 沢井製薬株式会社 | ビルダグリプチン含有コーティング粒子、ビルダグリプチン含有口腔内崩壊錠、ビルダグリプチン含有コーティング粒子の製造方法及びビルダグリプチン含有口腔内崩壊錠の製造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| DK1741445T3 (da) * | 2000-01-21 | 2013-11-04 | Novartis Ag | Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| WO2002030400A1 (fr) * | 2000-10-06 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Preparations solides |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| US20040186046A1 (en) * | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
| WO2005032590A1 (ja) * | 2003-10-03 | 2005-04-14 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
| KR20070068407A (ko) * | 2004-10-25 | 2007-06-29 | 노파르티스 아게 | Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물 |
-
2006
- 2006-05-24 GT GT200600218A patent/GT200600218A/es unknown
- 2006-06-03 SA SA6270158A patent/SA06270158B1/ar unknown
- 2006-06-08 WO PCT/US2006/022336 patent/WO2006135693A2/en active Application Filing
- 2006-06-08 PE PE2006000642A patent/PE20070165A1/es not_active Application Discontinuation
- 2006-06-08 JP JP2008515929A patent/JP2008543767A/ja active Pending
- 2006-06-08 EP EP06772588A patent/EP1893236A2/en not_active Withdrawn
- 2006-06-08 KR KR1020087000577A patent/KR20080018257A/ko not_active Application Discontinuation
- 2006-06-08 MX MX2007015612A patent/MX2007015612A/es unknown
- 2006-06-08 AR ARP060102392A patent/AR054382A1/es unknown
- 2006-06-08 CA CA002610412A patent/CA2610412A1/en not_active Abandoned
- 2006-06-08 US US11/916,490 patent/US20080193529A1/en not_active Abandoned
- 2006-06-08 BR BRPI0613567-6A patent/BRPI0613567A2/pt not_active IP Right Cessation
- 2006-06-08 AU AU2006258013A patent/AU2006258013A1/en not_active Abandoned
- 2006-06-09 TW TW095120636A patent/TW200716175A/zh unknown
-
2010
- 2010-08-24 AU AU2010212516A patent/AU2010212516A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010212516A1 (en) | 2010-09-16 |
| JP2008543767A (ja) | 2008-12-04 |
| CA2610412A1 (en) | 2006-12-21 |
| TW200716175A (en) | 2007-05-01 |
| US20080193529A1 (en) | 2008-08-14 |
| SA06270158B1 (ar) | 2010-10-23 |
| KR20080018257A (ko) | 2008-02-27 |
| EP1893236A2 (en) | 2008-03-05 |
| BRPI0613567A2 (pt) | 2011-01-18 |
| AU2006258013A1 (en) | 2006-12-21 |
| GT200600218A (es) | 2007-03-28 |
| AR054382A1 (es) | 2007-06-20 |
| MX2007015612A (es) | 2008-02-25 |
| WO2006135693A2 (en) | 2006-12-21 |
| WO2006135693A3 (en) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070165A1 (es) | Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazona | |
| PE20050686A1 (es) | Formulacion para compresion directa y proceso | |
| AR052878A1 (es) | Formulacion de compresion directa y proceso | |
| AR043315A1 (es) | Composiciones detergentes | |
| RU2010128019A (ru) | Пероральная диспергируемая таблетка | |
| PE20001036A1 (es) | Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso | |
| PE20090015A1 (es) | Preparacion solida | |
| NZ594022A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| PE20110583A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
| PE20130378A1 (es) | Formulaciones de apixaban | |
| PE20061373A1 (es) | Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida | |
| PE20121442A1 (es) | Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden | |
| EA200602294A1 (ru) | Жевательная таблетка, таблетка для рассасывания и таблетка для глотания, содержащая кальцийсодержащее соединение в качестве активного вещества | |
| JP2008536020A5 (es) | ||
| PE20140163A1 (es) | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| PE20110119A1 (es) | Asociacion entre ferroquina y artesunato para el tratamiento del paludismo | |
| AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
| JP2008515980A5 (es) | ||
| RU2008135718A (ru) | Композиции клопидогреля бисульфата | |
| EA201001108A1 (ru) | Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения | |
| CO6150180A2 (es) | Sales de bencimidazolil-piridil-eteres y formulaciones de las mismas | |
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| AR059045A1 (es) | Composicion farmaceutica y proceso | |
| RU2008103213A (ru) | Орально распадающийся порошок, содержащий цилостазол и маннит |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |